Neurobio Psychopharmacology

Neurobio Psychopharmacology

Neurobio Psychopharmacology 150 150 Peter

Neurobio Psychopharmacology

List the trade and generic name of the selected drug (Alprazolam (Xanax))
Upload a picture of the selected food or drug (optional)
List one FDA approved use and one off-label use for the selected drug
List one medicinal use for the selected food

Sample Paper

Neurobio Psychopharmacology

Alprazolam (Xanax) is a type of benzodiazepine medication. It is currently produced by Pfizer. It was approved by the U.S. Food and Drug Agency (FDA) in 1981 (Pfizer, 2020). This drug was approved for various uses including acute treatment of generalized anxiety disorder in adults.  Regarding dosage and administration, patients with generalized anxiety disorder are required to start oral dosage which is 0.25 mg to 0.5 mg. The patient is required to take it three times in a day. The maximum required daily dose is 4 mg, which is taken in divided doses (Pfizer, 2020). However, the healthcare provider is required to ensure the patient uses the lowest possible effective dose and regularly examine the need for continued treatment.

This drug is also prescribed off-label for the treatment of numerous health conditions. For instance, Xanax is prescribed for the treatment of premenstrual syndrome (PMS). This refers to the group of symptoms that take place before the first day of a woman’s period.  They vary from one woman to another. Therefore, some women experience mild abdominal cramps while others get severe pain and mood swings (Casper & Yonkers, 2019). The recommended dosage is 0.25mg PO q6-12hr. The treatment should be initiated on day 16-18 of menses (Pfizer, 2020).

The drug has other approved medical uses. For instance, it is recommended for treatment of panic disorder in adults. The patient is recommended to begin with an oral dosage of 0.5 mg three times daily (Pfizer, 2020).

References

Pfizer. (2020). XANAX-alprazolam tablet physician prescribing information. Retrieved from https://www.pfizer.com/products/product-detail/xanax

Casper, R. F., & Yonkers, K. A. (2019). Treatment of premenstrual syndrome and premenstrual dysphoric disorder. UpToDate, Inchttps://medilib.ir/index.php/uptodate/show/7382